The Future of BioPharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Future of BioPharma
Innovation resulting in improved productivity continues unabated and is a primary driver for many of the current biopharmaceutical trends. Innovation speeds discovery, drives down costs, and improves productivity.


Pharmaceutical Technology


The biopharmaceutical industry continues to evolve with expectations of a positive future. Much of this anticipation is driven by pressure for the next new thing, demand for better bioprocessing technologies, and by concerns about weak development pipelines. In response, most large pharmaceutical companies are now devoting increasing development efforts on biopharmaceuticals rather than small-molecule drugs. Some are now spending 40% or more of their R&D budget on biopharmaceuticals. The author examines the impact of these and other trends on the future direction of biomanufacturing.

RELATED EVENT : Manufacturing Execution Systems | Aug 13-14, 2013 - Philadelphia, PA http://www.cbinet.com/conference/pc13144?cid=ptarticlepagemeswebsite


MACIEJ FROLOW/GETTY IMAGES
Innovation resulting in improved productivity continues unabated and is a primary driver for many of the current biopharmaceutical trends. Innovation speeds discovery, drives down costs, and improves productivity. The current situation in the biopharmaceutical industry is exciting enough, with biosimilars, new technologies, personalized medicines, and opportunities in emerging markets. The industry, however, believes more opportunities for advancement are coming in the near future. Innovations are driving a number of major industry trends; and many ongoing trends, themselves, are driving innovation.

Biosimilars (and biobetters) are driving trends as well. With more than 700 biosimilars/biobetters in the development pipeline, there will be many more biopharmaceutical manufacturers and products, perhaps as many as a dozen or more for each emulated reference product. This pipeline will mean a lot more new biopharmaceutical industry players, ranging from virtual and foreign to the largest Big Pharma companies, with many new manufacturers and facilities. These competitors are expected to compete on the basis of price; therefore, low manufacturing costs will be required. This low-cost requirement is driving many companies to seek out and adopt bioprocessing innovations that achieve the most cost-effective manufacturing. Some of the biopharmaceutical trends coming in 2013 support a future vision that includes:
  • increasing number of global biopharma facilities
  • more biological products, many with smaller niches
  • more multiproduct facilities
  • adoption of single-use systems at clinical/commercial scale
  • continuous processing, including perfusion
  • high-tech expression systems and other genetic engineering advances
  • automation, monitoring, and process control
  • bioprocess modeling
  • modular facilities adaptable to new enabling technologies, with the ability to repurpose spaces.

Trend analytics

To gain perspectives on these and other trends, BioPlan Associates asked the 425 global subject matter experts and senior participants on its Biotechnology Industry Council to evaluate the current trends in bioprocessing and biopharmaceuticals. The more than 100 trends identified were categorized as follows:

  • 24% downstream process improvements
  • 22% single-use implementation and improvements
  • 24% analytical methods
  • 30% others: product platforms, cost reductions, materials sourcing, supply-chain regulatory compliance, biosimilars.

This relatively evenly distributed breakout suggests that the industry expects advancements in virtually all areas (see sidebar, "Key micro trends").

Demand for a better technology evaluation process

Rapid and cost-effective evaluation of new technologies is crucial to the industry achieving this expected progress. Evaluating new technologies in the regulated pharmaceutical environment can be slow and costly to both innovators and to the end-users doing the beta or evaluation testing. To reduce these challenges, BioPlan Associates has implemented a New Technology Evaluation Program (NTEP) to help kick-start innovation in bio/pharmaceutical manufacturing. The program helps ensure that the best technologies are eventually adopted by industry, even when their originators are small or resource constrained. The program benefits suppliers by providing high-value evaluations, rapidly getting new products into the right hands for testing, and coordinating multisite testing with integrated, compiled data and reporting. The program benefits those testing new products by giving them access to the most promising and cutting edge technologies while eliminating the need to deal with multiple contacts from multiple suppliers. This process can provide available data from other commercial evaluations as an unbiased resource and can rapidly integrate, publish, and disseminate these findings to industry.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here